SRC and cancer: Here, we evaluated the SRC/ABL kinase inhibitor, AZD0424, and its potential use as an anti‐cancer combination therapy by testing across a diverse range of in vitro and in vivo cancer models in parallel with quantitative pathway profiling at the post‐translational level.